Company profile: NanoSmart Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of platform drug delivery technologies for solid-tumor cancers, including a human-derived Anti-Nuclear Antibody targeting necrotic tumor tissue, ANA-conjugated lipid nanoparticles for direct API delivery to tumor sites, and a thermally sensitive nanoemulsion enabling stable storage and release at body temperature, plus licensing and partnerships to enhance existing cancer drugs.
Products and services
- ANA Targeted Nanoparticles: Lipid nanoparticles conjugated with ANA deliver active pharmaceutical ingredients directly to tumor sites, enhancing safety and efficacy in a tumor-targeted system
- Anti-Nuclear Antibody (ANA): Human-derived antibody that targets necrotic tissue in solid tumors, enabling universal targeting of all solid tumors for drug delivery in a tumor-agnostic modality
- Thermally Sensitive Nanoemulsion: Nanoemulsion platform enables stable storage of encapsulated drugs and controlled release at body temperature to improve delivery performance via a temperature-triggered mechanism
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NanoSmart Pharmaceuticals
CASI Pharmaceuticals
HQ: United States
Website
- Description: Provider of business development aimed at building a pipeline through mutually beneficial transactions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CASI Pharmaceuticals company profile →
2seventy bio
HQ: United States
Website
- Description: Provider of immuno-oncology cell therapies, discovering and developing cancer treatments, including ABECMA (idecabtagene vicleucel), a CAR T cell therapy for multiple myeloma developed in collaboration with Bristol Myers Squibb; leveraging expertise in cancer cell biology, genetics, and the immune response to advance its pipeline.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 2seventy bio company profile →
Provision Healthcare
HQ: United States
Website
- Description: Provider of cancer care and proton therapy, offering the ProNova SC360 system (360° treatment with superconducting magnets), integrated dual-energy CBCT for IGRT, fast-scanning IMPT, an independent energy selection system for instantaneous room switching, SBRT, and ARC radiation therapy, with a focus on improving patient care, outcomes, research, education, and charitable causes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Provision Healthcare company profile →
Albireo Pharma
HQ: Sweden
Website
- Description: Provider of novel bile acid modulators and therapeutic drugs for the treatment of pediatric and adult liver diseases and gastrointestinal diseases, with a focus on rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Albireo Pharma company profile →
Nanovi
HQ: Denmark
Website
- Description: Provider of biomaterials-based medical devices for improving guidance and precision in cancer radiotherapy. Offers BioXmark, a liquid fiducial marker that enhances target visibility on imaging for high-precision radiation therapy, including proton beam therapy; and PetXmark, a liquid fiducial marker for dogs and cats to radiographically mark subcutaneous tissue and guide radiotherapy of skin and subcutaneous tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanovi company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NanoSmart Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NanoSmart Pharmaceuticals
2.2 - Growth funds investing in similar companies to NanoSmart Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NanoSmart Pharmaceuticals
4.2 - Public trading comparable groups for NanoSmart Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →